Similar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease.

While the clinical presentation of posterior cortical atrophy is clearly distinct from typical Alzheimer's disease, neuropathological studies have suggested that most patients with posterior cortical atrophy have Alzheimer's disease with an atypical visual presentation. We analysed in vivo pathophysiological markers of Alzheimer's disease such as cerebrospinal fluid biomarkers and positron emission tomography imaging with ¹¹C-labelled Pittsburgh compound-B in posterior cortical atrophy to determine whether biochemical profile and fibrillar amyloid-β burden topography are associated with the clinical presentation. Nine patients with posterior cortical atrophy and nine with typical Alzheimer's disease individually matched for age, duration and severity of the disease and 10 cognitively normal age-matched controls were included. ¹¹C-labelled Pittsburgh compound-B images were analysed both using volumes of interest and on a voxel-wise basis using statistical parametric mapping, taking into account the individual regional cortical atrophy. Cerebrospinal fluid biomarkers did not differ between posterior cortical atrophy and patients with Alzheimer's disease. Compared with normal controls, both posterior cortical atrophy and Alzheimer's disease groups showed increased ¹¹C-labelled Pittsburgh compound-B uptake. No significant difference was found in regional or global ¹¹C-labelled Pittsburgh compound-B binding between posterior cortical atrophy and Alzheimer's disease groups with both volumes of interest and voxel-wise basis using statistical parametric mapping methods. Our findings demonstrate that cerebrospinal fluid biomarkers and positron emission tomography imaging with ¹¹C-labelled Pittsburgh compound-B may be useful in identifying an atypical visual form of Alzheimer's disease. The similar topography of fibrillar amyloid-β deposition between typical Alzheimer's disease and posterior cortical atrophy groups suggests that, although amyloid-β accumulation plays a critical role in the pathogenesis of Alzheimer's disease, other factors such as neurofibrillary tangles may contribute to the different clinical features observed in posterior cortical atrophy.

[1]  J. Morris The Clinical Dementia Rating (CDR) , 1993, Neurology.

[2]  D. Selkoe,et al.  Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. , 1989, The American journal of pathology.

[3]  M. Weiner,et al.  Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. , 2010, Brain : a journal of neurology.

[4]  M. Hüll,et al.  Posterior cortical atrophy: variant of Alzheimer’s disease? , 2005, Journal of Neurology.

[5]  R. Petersen,et al.  Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy , 2004, Neurology.

[6]  G. Ridgway CLINICAL SYNDROMES ASSOCIATED WITH POSTERIOR ATROPHY: EARLY AGE AT ONSET AD SPECTRUM , 2010, Neurology.

[7]  Alexander Hammers,et al.  Automatic segmentation of the hippocampus and the amygdala driven by hybrid constraints: Method and validation , 2009, NeuroImage.

[8]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[9]  Andrew J. Reader,et al.  Impact of Image-Space Resolution Modeling for Studies with the High-Resolution Research Tomograph , 2008, Journal of Nuclear Medicine.

[10]  K Patterson,et al.  Focal cortical presentations of Alzheimer's disease. , 2007, Brain : a journal of neurology.

[11]  L. Cohen,et al.  Neural correlates of cognitive impairment in posterior cortical atrophy. , 2011, Brain : a journal of neurology.

[12]  Nick C Fox,et al.  Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer's disease , 2011, Neurobiology of Aging.

[13]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[14]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[15]  K. Ishii,et al.  Posterior cortical atrophy with [11C] Pittsburgh compound B accumulation in the primary visual cortex , 2010, Journal of Neurology.

[16]  M. Sarazin,et al.  Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[18]  Lei Wang,et al.  Correlations Between Antemortem Hippocampal Volume and Postmortem Neuropathology in AD Subjects , 2004, Alzheimer disease and associated disorders.

[19]  C. Rowe,et al.  Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. , 2007, Archives of neurology.

[20]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[21]  A. Kertesz,et al.  The cognitive profile of posterior cortical atrophy , 2006 .

[22]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[23]  J. Aharon-Peretz,et al.  Posterior Cortical Atrophy Variants of Alzheimer’s Disease , 1999, Dementia and Geriatric Cognitive Disorders.

[24]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  A. Monsch,et al.  CSF-Tau and CSF-Aβ1–42 in Posterior Cortical Atrophy , 2010, Dementia and Geriatric Cognitive Disorders.

[26]  G. Linazasoro,et al.  IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.

[27]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[28]  J. A. Renner,et al.  Progressive posterior cortical dysfunction , 2004, Neurology.

[29]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[30]  Mark A Mintun,et al.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. , 2009, Archives of neurology.

[31]  M. Viitanen,et al.  Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease , 2006, Neurology.

[32]  D. Benson Posterior cortical atrophy , 1995 .

[33]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[34]  C. Jack,et al.  Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.

[35]  J. Trojanowski,et al.  CSF biomarkers in frontotemporal lobar degeneration with known pathology , 2008, Neurology.

[36]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[37]  Benson Df,et al.  Posterior cortical atrophy. , 1988, Archives of neurology.

[38]  J B Poline,et al.  Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. , 2007, Brain : a journal of neurology.

[39]  J. Hodges,et al.  The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer’s disease) with FDG-PET , 2003, Journal of neurology, neurosurgery, and psychiatry.